首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1566162

大肠直肠癌治疗药物市场规模、份额、成长分析、按药物类别、按癌症类型、按分销管道、按地区 - 行业预测，2024-2031 年

Colorectal Cancer Therapeutics Market Size, Share, Growth Analysis, By Drug Class, By Cancer Type, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球大肠直肠癌治疗市场规模预计为116亿美元，从2023年的121.7亿美元成长到2031年的178.4亿美元，预测期（2024-2031年）预计复合年增长率为4.9%。

全球大肠直肠癌治疗市场的发生率正在惊人地增加，这主要是由于久坐的生活方式、不健康的饮食选择和人口老化所致。先进诊断和筛检技术的引入促进了早期发现并实现了及时的治疗性介入。此外，癌症治疗领域的技术创新，例如标靶治疗、免疫疗法和联合治疗，可以提高治疗效果并改善患者的治疗结果，同时最大限度地减少副作用，也大大推动了市场的发展。然而，情况并非没有挑战。先进癌症治疗的高昂费用给医疗保健系统带来了沉重负担，并可能导致各地区的医疗服务不平等。此外，抗药性的出现使长期治疗效果变得复杂，并成为患者实现长期缓解的主要障碍。监管障碍和复杂的报销系统也构成了障碍，严格的医药品认证过程和不同的报销政策可能会限制获得先进治疗的机会。儘管存在这些障碍，美国结直肠癌药物市场仍将持续增长，预计在接下来的预测期内将实现稳定的年复合成长率（CAGR），这表明对对抗结直肠癌的创新解决方案的持续需求。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Amgen, Inc.（US）
Bayer AG（Germany）
Bristol-Myers Squibb Company（US）
Lilly（US）
Merck & Co., Inc.（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Sanofi（France）
Pfizer Inc.（US）
Novartis AG（Switzerland）
Regeneron Pharmaceuticals, Inc.（US）
AstraZeneca PLC（UK）
Gilead Sciences, Inc.（US）
Takeda Pharmaceutical Company Limited（Japan）
Ipsen Pharma（France）
Sumitomo Pharma Co., Ltd.（Japan）
Exelixis, Inc.（US）
BeiGene, Ltd.（China）
Oncolytics Biotech Inc.（Canada）
NantKwest, Inc.（US）
Eisai Co., Ltd.（Japan）
Incyte Corporation（US）
MacroGenics, Inc.（US）
Halozyme Therapeutics, Inc.（US）

简介目录

Product Code: SQMIG35A2691

Global Colorectal Cancer Therapeutics Market size was valued at USD 11.6 billion in 2022 and is poised to grow from USD 12.17 billion in 2023 to USD 17.84 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031).

The global colorectal cancer therapeutics market is experiencing robust growth driven by an alarming rise in the incidence of the disease, largely due to sedentary lifestyles, unhealthy dietary choices, and an increasingly aging population. The implementation of advanced diagnostic and screening techniques has facilitated early detection, enabling timely therapeutic interventions. Additionally, the market is significantly bolstered by innovations in cancer treatment, including targeted therapies, immunotherapies, and combination approaches that enhance treatment efficacy and improve patient outcomes while minimizing side effects. However, the landscape is not without challenges; the high costs associated with advanced cancer therapies present a substantial burden on healthcare systems, leading to potential inequities in access across different regions. Furthermore, the emergence of drug resistance complicates treatment efficacy over time, posing significant hurdles in achieving long-term remission for patients. Regulatory obstacles and intricate reimbursement systems also pose barriers, as stringent drug approval processes and variable reimbursement policies can restrict the accessibility of advanced therapies. Despite these hurdles, the US colorectal cancer therapeutics market is poised for sustainable growth, anticipated to achieve a steady compound annual growth rate (CAGR) in the upcoming forecast period, signaling a continued demand for innovative solutions in the fight against colorectal cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Colorectal Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Colorectal Cancer Therapeutics Market Segmental Analysis

Global Colorectal Cancer Therapeutics Market is segmented by Drug Class, Cancer Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Chemotherapy, Immunotherapy, and Others. Based on Cancer Type, the market is segmented into Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is significantly driven by a surge in awareness campaigns and comprehensive screening programs aimed at fostering early detection and diagnosis of colorectal cancer. As public health initiatives emphasize the importance of timely intervention, patients are increasingly accessing screenings that facilitate early identification of cancer, leading to improved treatment outcomes. This heightened awareness not only empowers individuals to seek appropriate medical care but also elevates the demand for innovative and effective therapeutics, as healthcare providers focus on optimizing treatment strategies for patients diagnosed at earlier stages of the disease. Consequently, this growing emphasis on early detection is a critical market driver.

Restraints in the Global Colorectal Cancer Therapeutics Market

A significant market restraint for the global colorectal cancer therapeutics market is the phenomenon of drug resistance that colorectal cancer cells can develop over time. This resistance diminishes the effectiveness of existing treatments, resulting in treatment failures and disease progression, which ultimately hampers patient survival rates. The challenge of overcoming this resistance complicates treatment protocols and necessitates the continuous development of new therapies, contributing to increased research and development costs. As a result, healthcare providers and pharmaceutical companies may face reduced treatment options and higher financial burdens, which can limit market growth and patient access to effective colorectal cancer therapeutics.

Market Trends of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is witnessing a notable trend towards the rising popularity of combination therapies. These innovative treatment approaches, which integrate chemotherapy, targeted therapy, and immunotherapy, are being increasingly explored for their ability to enhance therapeutic efficacy. By leveraging the synergistic effects of multiple modalities, combination therapies can significantly improve response rates, effectively tackle drug resistance, and ultimately prolong survival rates among colorectal cancer patients. This trend reflects a shift in treatment paradigms, as healthcare providers and researchers aim for more personalized, effective solutions in managing colorectal cancer, positioning combination therapies as a cornerstone in future therapeutic strategies.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Colorectal Cancer Therapeutics Market by Drug Class

Market Overview
Chemotherapy
Immunotherapy
Others

Colorectal Cancer Therapeutics Market by Cancer Type

Market Overview
Colorectal Adenocarcinoma
Gastrointestinal Carcinoid Tumors
Others

Colorectal Cancer Therapeutics Market byDistribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Colorectal Cancer Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Amgen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lilly (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene, Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncolytics Biotech Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MacroGenics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Halozyme Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments